Results 41 to 50 of about 27,075 (224)
, 2019 Objectives: Olaparib can improve progression-free survival compared with chemotherapy in patients with a BRCA mutation and HER2-negative metastatic breast cancer (MBC); however, this drug comes at a high price (AU$6,900/pack). This study aims to evaluate
Tuffaha, H, Scuffham, P
core +1 more source
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
BMC Cancer, 2020 Background Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) which inhibits binding of programmed cell death ligand
Jean-David Fumet +6 more
doaj +1 more source
Molecular Oncology, EarlyView.We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee +3 more
wiley +1 more source
Journal of Biomedical Science, 2022 Background Seaweed polysaccharides have been recommended as anticancer supplements and for boosting human health; however, their benefits in the treatment of triple-negative breast cancers (TNBCs) and improving immune surveillance remain unclear ...
Li-Mei Chen +7 more
doaj +1 more source
Translational Oncology, 2021 P-glycoprotein (P-gp) is an adenosine triphosphate (ATP)-dependent drug efflux protein commonly associated with multidrug resistance in cancer chemotherapy.
Yan Baglo +6 more
doaj +1 more source
PET imaging of PARP expression using [18F]olaparib [PDF]
, 2018 PARP inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, dose optimization ...
Kersemans, V +31 more
core +1 more source
Advanced Science, EarlyView.Chromosome 16q loss drives genomic instability through disruption of the CYLD–TIRR–53BP1 axis. CYLD preserves homologous recombination by stabilizing TIRR and limiting 53BP1 accumulation at DNA double‐strand breaks. CYLD deficiency redirects repair toward error‐prone non‐homologous end joining, promotes mutational burden and homologous recombination ...
Mingming Lu +14 more
wiley +1 more source
Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance
Frontiers in Oncology, 2022 Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases.
Mohammed Hafiz Uddin +13 more
doaj +1 more source
Advanced Science, EarlyView.An interpretable, unsupervised artificial intelligence framework identifies a 13‐cellular morphometric biomarker (CMB) signature from routine H&E whole‐slide images. Validated across 2,602 patients, the fixed signature generalizes across colorectal, gastric, and esophageal tissues without retraining, stratifies prognosis and precancerous lesion risk ...
Pin Wang +14 more
wiley +1 more source